Green Automotive Company Corp. (OTCQB: GACR) saw its share volume skyrocket on May 22nd with 13,436,426 shares exchanging hands, nearly four times higher than its three month daily average volume of 3,609,991 shares.
This surge in volume comes after the company reported its financial results for the first quarter, ended March 31st, 2014. The company posted strong quarterly revenue of $1.235m, up from $218K reported for Q1 2013. This major increase is largely attributable to strong growth in sales at our Newport Coachworks business.
"We are proud of our quarterly results, especially our record shuttle bus sales that we started manufacturing only in February 2013. We are experiencing strong demand for our high quality buses, especially our CNG models that allow customers to reduce CO2 emissions and total cost of ownership," said Ian Hobday, CEO of Green Automotive Company. "The success we encountered at our first major show, the LCT in Las Vegas, confirmed the competitive advantages of our product as we took orders for $1.6m. We have now finalized the build and testing of our electric shuttle bus and we are excited to start rolling out our launch program at the Government Fleet EXPO early June."
GACR closed the day at $.029 on May 22nd, 12.4% higher than its previous close of $.0258.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
OncoSec Sees Share Volume Plummet
OncoSec Medical Inc. (OTCQB: ONCS) saw its share volume plummet on May 22nd with 759,018 shares exchanging hands, significantly lower than its three month daily average volume of 3,266,950 shares.
With no recent news, here is what is known about the company:
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response while minimizing the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma.
ONCS closed the day at $.77 on May 22nd.
Advanced Cell Technology, Inc. Sees Share Volume Remain Steady
Advanced Cell Technology, Inc. (OTCQB: ACTC) saw its share volume remain steady on May 22nd with 8,697,313 shares exchanging hands, slightly lower than its three month daily average volume of 11,061,558 shares.
Advanced Cell Technology, Inc., (ACTC) is a Marlborough, Massachusetts based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration and Stargardt’s macular degeneration. These cell therapies are also clinical trial candidates for the treatment of myopic macular degeneration. ACTC’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
ACTC closed the day at $.0599 on May 22nd.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.